Trial Profile
A Multicentre, Retrospective Cohort study to evaluate the predictors of response to Nivolumab in patients with Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jan 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Jan 2018 New trial record
- 01 Jan 2018 Results published in the Anticancer Research